Go Pro
OTCMKTS:MCUJF

Medicure Q2 2026 Earnings Report

Medicure logo
$1.90 0.00 (0.00%)
As of 02:46 PM Eastern

Medicure EPS Results

Actual EPS
-$0.10
Consensus EPS
-$0.05
Beat/Miss
Missed by -$0.05
One Year Ago EPS
N/A

Medicure Revenue Results

Actual Revenue
$5.36 million
Expected Revenue
$2.45 million
Beat/Miss
Beat by +$2.91 million
YoY Revenue Growth
N/A

Medicure Announcement Details

Quarter
Q2 2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Medicure's next earnings date is estimated for Thursday, November 19, 2026, based on past reporting schedules.

Conference Call Resources

Medicure Earnings Headlines

Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
See More Medicure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Medicure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Medicure and other key companies, straight to your email.

About Medicure

Medicure (OTCMKTS:MCUJF) is a Winnipeg, Manitoba-based specialty pharmaceutical company focused on developing, commercializing and distributing therapies for cardiovascular and related medical conditions. The company serves healthcare markets primarily in North America through its operating subsidiaries and commercial partners.

Medicure’s product portfolio includes AGGRASTAT (tirofiban hydrochloride), an intravenous antiplatelet medication used in the treatment of certain patients with acute coronary syndrome and during percutaneous coronary intervention. The company also markets ZYPITAMAG (pitavastatin), an oral statin used to help manage elevated cholesterol levels.

Medicure has historically concentrated on specialty cardiovascular products and has sought to expand its presence through product development, licensing and commercialization activities. The company is led by Dr. Albert D. Friesen, who serves as president and chief executive officer.

View Medicure Profile